NYSE:TEVAPharmaceuticals
Teva (TEVA) Is Up 17.0% After Return to Profit and New Institutional Support Has the Bull Case Changed?
Teva Pharmaceutical Industries recently reported third-quarter 2025 results, showing a return to profitability with net income of US$433 million on sales of US$4.48 billion, and provided updated revenue guidance for 2025 and long-term sales targets.
Institutional investment increased, highlighted by Phoenix Financial’s large share purchase, as Teva continued to execute its turnaround plan and expand efforts in branded medicines and biosimilars.
Against this backdrop, we'll consider how...